PeptiSystems and Asahi Kasei Bioprocess America enter exclusive global partnership for peptide synthesis

15th of May, 2025 - Uppsala, Sweden,

​

PeptiSystems, a biotech company specializing in innovative manufacturing solutions for peptide and oligonucleotide drugs, has formed an exclusive global partnership with Asahi Kasei Bioprocess America (AKBA), a leading provider of advanced bioprocessing equipment solutions. The collaboration combines PeptiSystems’ flow-through instrument platform with AKBA’s high-performance column technology – giving customers a streamlined and reliable setup from the very first run.

​

As part of the partnership, PeptiSystems will incorporate the THESYS® ACS Ergo synthesis column – developed by Asahi Kasei Bioprocess America (AKBA) for large-scale oligonucleotide manufacturing – into its large-scale peptide synthesis platform, the PeptiPro®. This enables shorter changeover times between batches while maintaining user safety and product quality, and supports high-performance, scalable production for state-of-the-art peptide manufacturing.

​

“By integrating a proven and high-quality column into our platform, we can offer a complete, ready-to-use solution that helps customers accelerate development and reduce risk,” says Karin Granath, CEO of PeptiSystems. “It’s a strategic step that strengthens our offering and supports future growth in both research and manufacturing applications.”

“We see this partnership as a natural step in bringing next-generation peptide solutions to the TIDES market,” says Chris Rombach, President of Asahi Kasei Bioprocess America. “By combining our column expertise with PeptiSystems’ innovative synthesis platform, we’re enabling customers to access a complete, integrated solution.”

​

PeptiSystems’ proprietary flow-through, column-based technology optimizes synthesis efficiency, reduces material waste, and meets the highest standards of quality and reproducibility. By enabling pharmaceutical companies and CDMOs to scale production of complex peptide and oligonucleotide therapeutics, the platform supports the transition to next-generation manufacturing. The company continues to expand its offering, with a focus on innovation, integration, and customer value.

​

For more information, please contact:
Karin Granath, CEO
Phone: +46 702-82 07 47
Email: karin.granath@peptisystems.com

​

About PeptiSystems AB
PeptiSystems is a biotech company developing a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Utilizing proprietary flow-through column technology, PeptiSystems' instruments significantly reduce production times, enhance synthesis control, and minimize raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for high-performance, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, please visit www.peptisystems.com and follow us on LinkedIn.

​

About Asahi Kasei Bioprocess
The Fluid Management Business Unit of Asahi Kasei Bioprocess is devoted to solving therapeutic product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for oligonucleotide synthesis, buffer formulation, chromatography, and filtration, our bioprocess systems, columns, and automation solutions advance GMP manufacturing of critical drug substances worldwide. Built with pride, built with quality, built to exceed expectations. “Built for You.” For more information, please visit https://fluidmgmt.ak-bio.com.

The Purification Business Unit of Asahi Kasei Bioprocess provides a growing range of innovative hollow-fiber purification products that help biotherapeutics manufacturers safely and efficiently produce medicines that patients can trust under the philosophy: “Assurance Beyond Expectation.” Beginning in 1989 with the launch of Planova™, the world’s first virus removal filter, our pioneering tradition of supplying exceptionally reliable bioprocess consumables has continued with the launches of several next-generation virus removal filters and purification and clarification products. For more information, please visit https://planova.ak-bio.com.

​

About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people worldwide. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. For more information, visit www.asahi-kasei.com.

Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.